Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paridiprubart - Edesa Biotech

Next Previous
Drug Profile

Paridiprubart - Edesa Biotech

Alternative Names: EB 05; EB-07; NI-0101

Latest Information Update: 27 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NovImmune SA
  • Developer Edesa Biotech; Light Chain Bioscience
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III SARS-CoV-2 acute respiratory disease
  • Phase II Adult respiratory distress syndrome
  • Preclinical Idiopathic pulmonary fibrosis
  • Discontinued Rheumatoid arthritis; Systemic scleroderma

Most Recent Events

  • 24 Feb 2026 Edesa Biotech files provisional patent applications with the USPTO for EB 07 for the treatment of Sepsis, Acute kidney injury, and Pneumonia
  • 24 Feb 2026 Updated adverse event and efficacy data from a phase II/III trial in SARS-COV-2 acute respiratory disease released by Edesa Biotech
  • 17 Dec 2025 9456733- No updates; info already covered

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top